It is a long established fact that a reader of a page when looking at its layout.

    ALyS™505N & ALyS™705

    Serum free medium for the activation and expansion of Human Lymphocyte

    Product Basics

    ALyS™505N is a serum-free and xeno-free medium used for the expansion and activation of human lymphocytes. It is available in four different IL-2 concentrations, suitable for activating or expanding T cells from human lymphocytes. Higher concentrations of IL-2 activate T cells, while lower concentrations are used for expansion. Gas-permeable culture bags are available for IL-2-free and 175 uL/mL media. Additionally, higher cell proliferation can be achieved by adding a small amount of Artificial Serum.

     

    ALyS™705 is a serum-free, animal-free, and chemically defined medium used for the expansion and activation of human lymphocytes. Unlike ALyS™505N, ALyS™705 achieves an animal-free culture environment by utilizing a high molecular weight polymer instead of albumin, which reduces shear stress between cells. When supplemented with Artificial Serum, ALyS™705 has demonstrated higher proliferation rates than ALyS™505N.

    Lymactin-T, an anti-CD3 monoclonal antibody produced by the hybridoma OKT3 in a serum-free environment, complements the ALyS™505n & 705. It induces strong proliferation by binding to CD3 on T cells derived from peripheral blood, enhancing the activation and expansion process.

    Key Features

    Technical Information

    High Cell Proliferation

    Anti-CD3 activated lymphocytes from peripheral blood (T cells) are cultured for 5 days to measure cell proliferation.

    Fig. 1
    ALyS™505N (blue) can maintain high proliferation of anti-CD3 activated lymphocytes as effectively as Medium A (orange), and more efficiently than RPMI-1640 with 10% serum (green)

    Comparison of ALyS™505N and ALyS™705

    Anti-CD3 activated lymphocytes (T-cells) cultured in ALyS™705 and ALyS™505N showed similar cell proliferation.

    Fig. 2
    Anti-CD3 activated lymphocytes (T-cells) cultured in ALyS™705 demonstrated similar proliferation rates to those cultured in ALyS™505N. The addition of 1% human serum boosted cell proliferation in both mediums. With 1% human serum supplementation, ALyS™705 showed higher proliferation than ALyS™505N.

    Both media were supplemented with IL-2 at 700IU/mL on day 0. The concentration of IL-2 was reduced to 175IU/mL when medium was added on days 2, 3, and 4. There was no medium refreshment on days 5 and 6

    Specification

    Scroll to right

    SKUProductDescriptionSizeContentsStorage
    1020P10/1020C10ALyS505N-0IL-2 free1LBottle/Culture Bag4°C
    10217P10/10217C10ALyS505N-175IL-2 concentration 175lU/mL (Expansion)1LBottle/Culture Bag4°C
    1027P10ALyS505N-7IL-2 concentration 700lU/mL
    (Activation)
    1LBottle4°C
    10210P10ALyS505N-10IL-2 concentration 1,000lU/mL (Activation)1LBottle4°C
    120P10ALyS705IL-2 free1LBottle4°C

     

    • Manufactured by: Cell Science and Technology Institute

    Pricing

    ALyS™505N & ALyS™705

    ALyS505N-0/IL-2 Free
    • SKU: 1020P10
    • Size: 1L (Bottle)
    • Price: $110.00$100.00
    • SKU: 1020C10
    • Size: 1L (Culture Bag)
    • Price: Contact us

    /

    ALyS505N-175/IL-2 175IU/ml
    • SKU: 10217P10
    • Size: 1L (Bottle)
    • Price: $130.00$117.00
    • SKU: 10217C10
    • Size: 1L (Culture Bag)
    • Price: Contact us
    ALyS505N-7/IL-2 700IU/ml
    • SKU: 1027P10
    • Size: 1L (Bottle)
    • Price: $210.00$190.00
    ALyS505N-10/IL-2 1000IU/ml
    • SKU: 10210P10
    • Size: 1L (Bottle)
    • Price: $315.00$285.00
    • SKU: 120P10
    • Size: 1L (Bottle)
    • Price: $270.00$243.00

    Complement Products

    Xeno Free
    • SKU: A2G10P2CC
    • Size: 20ml
    • Price: $500.00$450.00
    Animal Free
    • SKU: A2G10P2CC
    • Size: 20ml
    • Price: $850.00$765.00

    Lymactin-T

    • SKU: 6001T01
    • Size: 1mL (2.4mg/mL)
    • Price: $350

    References

    ALyS™505N

    1. Xu, X., Wu, Y., Xu, Y., Mao, W. & Pan, Y. Macrophages Promote Atherosclerosis Development by Inhibiting CD8T Cell Apoptosis. Mediators of Inflammation 2024, 1929766 (2024) doi: 1155/2024/1929766.
    2. Wang, S. et al. Hepatocellular carcinoma-specific epigenetic checkpoints bidirectionally regulate the antitumor immunity of CD4 + T cells. Cellular & Molecular Immunology 21, 1296–1308 (2024) doi: 1038/s41423-024-01215-0.
    3. Wang, K. et al. PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic cancer. Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease 1870, 167236 (2024) doi: 1016/j.bbadis.2024.167236.
    4. Toyofuku, T., Ishikawa, T., Nojima, S. & Kumanogoh, A. Efficacy against Lung Cancer Is Augmented by Combining Aberrantly N-Glycosylated T Cells with a Chimeric Antigen Receptor Targeting Fragile X Mental Retardation 1 Neighbor. The Journal of Immunology 212, 917–927 (2024) doi: 4049/jimmunol.2300618.

    ALyS™705

    1. Mitsuno, K. et al. Selective JAK2 pathway inhibition enhances anti-leukemic functionality in CD19 CAR-T cells. Cancer Immunology, Immunotherapy 74, 79 (2025) doi: 1007/s00262-024-03927-8.
    2. Suematsu, M. et al. Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangement. Cancer Immunology, Immunotherapy 72, 957–968 (2023) doi: 1007/s00262-022-03303-4.
    3. Chinsuwan, T. et al. Ligand-based, piggyBac-engineered CAR-T cells targeting EGFR are safe and effective against non-small cell lung cancers. Molecular Therapy – Oncolytics 31, (2023) doi: 1016/j.omto.2023.100728.

    Click here for more references!

    FOR RESEARCH USE ONLY, NOT FOR USE IN DIAGNOSTIC PROCEDURES